Learn More


Leading the way in the fight against arterial calcium




Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary artery disease. Our primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications it presents for the millions who suffer from peripheral artery disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe and effective medical devices to help improve patient outcomes.

We have developed patented orbital atherectomy systems (OAS) technology for both peripheral and coronary commercial applications.

Our peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee and address many of the limitations associated with other treatment alternatives.

Our coronary product is a catheter-based platform designed to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions. The Coronary OAS design is similar to technology used in our Peripheral OAS, customized specifically for the coronary application.


Vision

To treat the symptoms of cardiovascular disease as a barrier to living a full life by providing awareness, education and innovation.

Leading the way to help treat arterial calcium

Committed to getting people with PAD and CAD back to what matters

Collaborating with leading experts

Timeline

2017

Diamondback 360® Coronary Orbital Atherectomy System (OAS) Micro Crown Received FDA Approval in the U.S. and MHLW Approval in Japan

2017

First Patient Enrolled in ECLIPSE Trial

Largest Coronary Atherectomy Trial to Date to Study OAS vs. Conventional Angioplasty Prior to Drug-eluting Stent Implantation for the Treatment of Severely Calcified Lesions

2015

COAST Study Enrollment Completed

Study to Support Approval of Coronary OAS Micro Crown in the U.S. and Japan

2015

Moved Into New Corporate Headquarters

Moved Into New Corporate Headquarters

2014

Low-profile Diamondback 360<sup>®</sup> Peripheral OAS Received FDA Clearance

Low-profile Diamondback 360® Peripheral OAS Received FDA Clearance

2014

CONFIRM Study Published

Peripheral OAS Registry

2013

Diamondback 360<sup>®</sup> Coronary OAS Classic Crown Received FDA Approval

Diamondback 360® Coronary OAS Classic Crown Received FDA Approval

2012

CALCIUM 360º Study Published

Peripheral OAS Study in Below-the-Knee Lesions

2012

ORBIT II Study Enrollment Completed

Pivotal Study for Coronary OAS Classic Crown Conducted in the U.S.

2011

Stealth 360<sup>®</sup> Peripheral OAS Launched

Stealth 360® Peripheral OAS Launched

2010

First Patient Enrolled in ORBIT II Study

2010

COMPLIANCE Study Enrollment Completed

Peripheral OAS Study in Above-the-Knee Lesions

2009

CSI Goes Public (NASDAQ: CSII)

2008

ORBIT I Study Enrollment Completed

Feasibility Study for Coronary OAS Classic Crown Conducted in India

2007

Peripheral Orbital Atherectomy System (OAS) Received FDA Clearance

2003

Name Changed to Cardiovascular Systems, Inc.

1997

Orbital Atherectomy Device Designed

1989

Shturman Cardiology Systems, Inc., Formed


Discover the orbital atherectomy solution for arterial calcium


CSI_Arrows_White

CSI can help improve outcomes for patients with peripheral artery disease (PAD) and coronary artery disease (CAD),4-6 Our Diamondback 360® Orbital Atherectomy Systems (OAS) apply an innovative mechanism of action to treat complex calcium for both disease states.

Our Coronary OAS is the only device specifically indicated for severe coronary calcium, Diamondback 360 reduces calcified plaque, enabling successful stent deployment to help optimize PCI outcomes.

The Peripheral OAS offers multiple access solutions through its low profile technology to help physicians remove calcified lesions from hip to heel.35



Come work with us


CSI offers an exciting culture and rewarding career opportunities. If you share our passion for innovative, real-world solutions with the goal of improving patient care and quality outcomes, then consider joining us. Review our open positions, complete an application, and learn how you can become part of the CSI team.


CSI is an EEO/AA company: Women, Minorities, the Disabled and Veterans are encouraged to apply. If you are a job seeker with a disability and require accessibility assistance or reasonable accommodation to apply for an open position, please contact the Recruiting Department at CSI, 1255 Old Hwy 8, New Brighton MN 55112 or call (651) 259-1600.


Patient Stories

Helping people get back to what matters